Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 46 articles: HTML format

Single Articles

October 2026
1. FIALKOFF G, Takahashi N, Sharkia I, Gutin J, et al
   Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer.
   J Clin Invest. 2026;136:e202151.
   PubMed     Abstract available
   
   
   July 2026
2. HO R, Mills JC
   Cellular plasticity as a therapeutic vulnerability: HNF4alpha is a key target in lung adenocarcinoma.
   J Clin Invest. 2026;136:e207473.
   PubMed     Abstract available
   
   
   
3. ESSEL DADZIE H, Green YS, Camolotto SA, Arnold HU, et al
   HNF4alpha controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.
   J Clin Invest. 2026;136:e198282.
   PubMed     Abstract available
   
   
   May 2026
4. ZOU T, Minna JD
   Understanding immune checkpoint inhibitor efficacy through spatial decoding of the lung cancer tumor immune microenvironment.
   J Clin Invest. 2026;136:e206316.
   PubMed     Abstract available
   
   
   
5. ISOMOTO K, Haratani K, Tsujikawa T, Tomida S, et al
   Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC.
   J Clin Invest. 2026;136:e195021.
   PubMed     Abstract available
   
   
   
6. XING W, Zhou Y, Haedicke K, Wang C, et al
   Label-free streamlined photoacoustic image guidance facilitates NIR-II photoablation in models of melanoma lung metastases.
   J Clin Invest. 2026;136:e196095.
   PubMed     Abstract available
   
   
   April 2026
7. ZHAO Y, Zhou Y, Pan L, Tian GG, et al
   Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance.
   J Clin Invest. 2026;136:e191735.
   PubMed     Abstract available
   
   
   March 2026
8. ZHUANG WT, Pang LL, Hu LY, Liao J, et al
   EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-gamma.
   J Clin Invest. 2026;136:e194377.
   PubMed     Abstract available
   
   
   February 2026
9. BURNS TF, Dacic S, Chakka A, Miller E, et al
   MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.
   J Clin Invest. 2025;136:e194708.
   PubMed     Abstract available
   
   
   
10. LI H, De Santis MC, Tucci FA, Tosoni D, et al
    SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
    J Clin Invest. 2026;136:e192705.
    PubMed     Abstract available
    
    
    
11. GHOSH M, Wu C, Kumar A, Nilsson M, et al
    Osimertinib activates a TGF-beta2-dependent secretory program that drives lung adenocarcinoma progression.
    J Clin Invest. 2025;136:e198418.
    PubMed     Abstract available
    
    
    January 2026
12. KENT JR, Abbott KL, Nordgren R, Deik A, et al
    Intraoperative arteriovenous patient sampling to assess in situ non-small cell lung cancer metabolism.
    J Clin Invest. 2026 Jan 27:e198821. doi: 10.1172/JCI198821.
    PubMed    
    
    
    December 2025
13. QIU Z, Song NJ, Li A, Singh D, et al
    PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation.
    J Clin Invest. 2025 Dec 18:e193354. doi: 10.1172/JCI193354.
    PubMed     Abstract available
    
    
    November 2025
14. HAJI S, Ogawa Y
    TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases.
    J Clin Invest. 2025;135:e198802.
    PubMed     Abstract available
    
    
    
15. LIU B, Dai Y, Wang Z, Song J, et al
    TET3 is a common epigenetic immunomodulator of pathogenic macrophages.
    J Clin Invest. 2025;135:e194879.
    PubMed     Abstract available
    
    
    October 2025
16. DRAGONI F, Sop J, Gurumurthy I, Beckey TP, et al
    Selective targeting of HIV infected clones by cognate peptide stimulation and antiproliferative drugs.
    J Clin Invest. 2025 Oct 21:e197266. doi: 10.1172/JCI197266.
    PubMed     Abstract available
    
    
    
17. ZENG C, Wang X, Zhong J, Zhang Y, et al
    PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma.
    J Clin Invest. 2025;135:e191040.
    PubMed     Abstract available
    
    
    
18. RAINES B, Tseng-Rogenski S, Dowdican AC, Peris I, et al
    A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer.
    J Clin Invest. 2025 Oct 14:e193790. doi: 10.1172/JCI193790.
    PubMed     Abstract available
    
    
    September 2025
19. KRATZMEIER C, Taheri M, Mei Z, Lim I, et al
    Lung adenocarcinoma-derived IFN-gamma promotes growth by modulating CD8+ T cell production of CCR5 chemokines.
    J Clin Invest. 2025;135:e191070.
    PubMed     Abstract available
    
    
    August 2025
20. XIONG T, Wang G, Yu P, Li Z, et al
    CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors.
    J Clin Invest. 2025;135:e189920.
    PubMed     Abstract available
    
    
    July 2025
21. KIM YS, Nabet BY, Cortez BN, Sun NY, et al
    NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.
    J Clin Invest. 2025 Jul 8:e185423. doi: 10.1172/JCI185423.
    PubMed     Abstract available
    
    
    June 2025
22. DESAI SS, Salahuddin S, Yusuf R, Ranjan K, et al
    Tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV.
    J Clin Invest. 2025 Jun 3:e177310. doi: 10.1172/JCI177310.
    PubMed     Abstract available
    
    
    
23. LEE S, Park J, Cho S, Kim EJ, et al
    Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells.
    J Clin Invest. 2025;135:e180570.
    PubMed     Abstract available
    
    
    May 2025
24. APPADURAI MI, Chaudhary S, Shah A, Natarajan G, et al
    ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer.
    J Clin Invest. 2025;135:e186863.
    PubMed     Abstract available
    
    
    April 2025
25. O'KEEFE S, Wang Q
    ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non-small cell lung cancer.
    J Clin Invest. 2025;135:e191094.
    PubMed     Abstract available
    
    
    
26. WANG S, Guo H, Fukushima R, Terajima M, et al
    Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression.
    J Clin Invest. 2025;135:e189197.
    PubMed     Abstract available
    
    
    
27. JIAO M, Guo Y, Zhang H, Wen H, et al
    ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer.
    J Clin Invest. 2025;135:e181517.
    PubMed     Abstract available
    
    
    March 2025
28. SHEN S, Zhang Q, Wang Y, Chen H, et al
    Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models.
    J Clin Invest. 2025;135:e185278.
    PubMed     Abstract available
    
    
    February 2025
29. YU F, Zheng S, Yu C, Gao S, et al
    KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Post-translational Modifications in Lung Cancer.
    J Clin Invest. 2025 Feb 4:e185149. doi: 10.1172/JCI185149.
    PubMed     Abstract available
    
    
    December 2024
30. LI D, Geng K, Hao Y, Gu J, et al
    Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
    J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249.
    PubMed     Abstract available
    
    
    October 2024
31. HUANG Q, Tian N, Zhang J, Song S, et al
    Nonclassical action of Ku70 promotes Treg-suppressive function through a FOXP3-dependent mechanism in lung adenocarcinoma.
    J Clin Invest. 2024;134:e178079.
    PubMed     Abstract available
    
    
    September 2024
32. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    PubMed     Abstract available
    
    
    June 2024
33. PARDO L, Norman JC
    Targeting the secretory program of 3q-amplified lung cancers.
    J Clin Invest. 2024;134:e181798.
    PubMed     Abstract available
    
    
    May 2024
34. MILLS GB, Labrie M
    Enhancing anticancer activity of macrophages through rational drug combinations.
    J Clin Invest. 2024;134:e180512.
    PubMed     Abstract available
    
    
    April 2024
35. HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al
    Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
    J Clin Invest. 2024;134:e168318.
    PubMed     Abstract available
    
    
    
36. TAN AC, Cook SL, Khasraw M
    Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
    J Clin Invest. 2024;134:e179352.
    PubMed     Abstract available
    
    
    March 2024
37. VACCARO K, Allen J, Whitfield TW, Maoz A, et al
    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    J Clin Invest. 2024;134:e169315.
    PubMed     Abstract available
    
    
    
38. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    PubMed     Abstract available
    
    
    January 2024
39. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available
    
    
    
40. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    PubMed     Abstract available
    
    
    December 2023
41. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    PubMed     Abstract available
    
    
    
42. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    PubMed     Abstract available
    
    
    November 2023
43. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed     Abstract available
    
    
    October 2023
44. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    PubMed     Abstract available
    
    
    
45. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    PubMed     Abstract available
    
    
    
46. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum